凯时合并促肝细胞生长素治疗重症肝炎临床研究

Clinical study on the effects of combining alplrosladil with injectic hepatic growth factor therapy in patients with severe hepatitis

目的探讨凯时(前列腺素E1脂微球载体制剂)与促肝细胞生长素联合应用对重症肝炎的疗效。方法将88例重症肝炎患者随机分为两组,凯时与促肝细胞生长素联合应用组(治疗组)45例,对照组43例。在综合治疗的基础上,治疗组加用凯时10μg和促肝细胞生长素120μg,对照组用促肝细胞生长素120μg,两组药物均溶于5%葡萄糖溶液250ml中静脉滴注,每日1次,疗程均为4周。结果治疗组疗效明显优于对照组(P<0.01),病死率明显降低(P<0.05)。结论凯时与促肝细胞生长素联合应用治疗重症肝炎有较好的疗效。

Objective To study the effect of combining alplrosladil（Lipo-PGE1）with injectic hepatic growth factor therapy in patients with severe hepatitis. Methods 88 patients with severe hepatitis were devided into two groups at random with 45 patients in the treated group and 43 patients in the control group. On the basis of using comprehensive therapeusis,the treated group was added with alprosladil injection 10μg and injeetie hepatic growth factor 120 μg for 4 weeks,the control group added with injeetie hepatic growth factor 120μg only for 4 weeks,both in 5% glucose injection 250 ml ,intravenous drip once a day. Resuits The curative effect of the treated group was much better than that of the control group（P〈0. 01）. The fatality rate of the treated group was significantly lower than that of the control group （P〈O. 05）. Conclusion Combining alplrosladil（Lipo-PGE1） with injeetic hepatic growth factor is more effective in the treatment of severe hepatitis.